Introduction
============

"Human chronic myeloid leukemia (CML) is a myeloproliferative disorder (MPD) caused by the Philadelphia chromosome translocation, a t (9; 22) that generates the BCR/ABL fusion oncoprotein" ([@B1]).

The BCR-ABL fusion protein is a constitutively active tyrosine kinase. Normally, this kinase precisely regulates downstream genes, including c-Myc, Akt and Jun, all of which are major players to the proliferation and survival of normal cells. However, the hyperactivity of the BCR-ABL kinase upsets this fine balance and propels cells towards uncontrolled proliferation and survival, both of which provide a growth advantage to the malignant cells bearing this mutation, ultimately leading to CML ([@B2]).

Next generation sequencing has proven to be an effective tool to identify recurrent, specific mutations in solid tumors and leukemias. Although the genetic heterogeneity of cancer necessitates some warn in the interpretation and application of the NGS results ([@B3], [@B4]), high-throughput sequencing remains a powerful instrument to refine potentially cancer diagnosis and treatment ([@B5]).

The aim of this study was to gain insights into the genetic alterations other than BCR-Abl translocation in molecular level, which finally cause CML. We performed whole-exome sequencing of four cases representative of BCR-ABL positive CML in chronic phase of the disease.

Material and Methods
====================

This study was conducted in Tarbiat Modares University Tehran, Iran in 2014. We used exome sequencing technology to identify mutations in molecular level in four individuals with CML who had given informed consent for sample collection and analysis. CML diagnosis was suspected by the Complete Blood Count (CBC) testing and then confirmed by identifying BCR-Abl translocation by real-time PCR. The selected patients were in chronic phase of CML without any other interfering disease and they received no treatment before sampling. DNA was extracted from peripheral blood using the conventional salting-out method. The qualifying DNA samples were exome sequenced by BGI (Beijing Genomics Institute).

Exome sequencing procedures and data analysis
---------------------------------------------

First, genomic DNA was randomly cleaved into a fragment library, purified and subsequently enriched by NimbleGen 2.1M-probe sequence capture array. The enriched library targeting the exome was sequenced on the Illumina HiSeq 2000 platform to acquire paired-end reads with a read length of 90 base pairs. After removing reads containing sequencing adapters and low-quality reads with more than five unknown bases, high-quality reads were aligned with the human genome reference sequence (hg19/GRCh37) using Bowtie2 software 27 with default parameters. The PCR duplicates detected from Alignment files were subsequently removed with Picard (<http://picard.sourceforge.net/>) to improve alignment accuracy. The Genome Analysis Toolkit (GATK) was then employed for base quality recalibration, local realignment around the potential insertion/deletion (Indel) sites and variant calling. The raw single nucleotide variants were filtered for low mapping quality, low coverage, SNP clusters, etc.

Then, the filtered variants were annotated using ANNOVAR for the following parameters: function (exonic or splicing); gene; exonic function (synonymous, nonsynonymous, stop gain, non-frameshift or frameshift indels); amino acid change; conservation; dbSNP (version 135) reference number; allele frequency in 1000 Genomes Project (2012 Feb version).

Results
=======

Data characteristics of exome sequencing of four samples are shown in [Table 1](#T1){ref-type="table"}. Statistics of annotated variants in four samples before and after filtering are listed in [Table 2](#T2){ref-type="table"}. We also prepared a list of all genes already involved in CML reported in publications summarized in [Table 3](#T3){ref-type="table"}.

###### 

Whole exome sequencing characteristics

  **Items/samples**                                       **23022**   **23031**   **23652**   **23878**
  ------------------------------------------------------- ----------- ----------- ----------- -----------
  Total effective reads                                   51161535    51082069    50259766    50395087
  Total effective yield (Mb)                              4532.41     4522.97     4444.54     4470.17
  Average read length (bp)                                88.59       88.54       88.43       88.7
  Average sequencing depth on target                      56.7        56.12       56.14       56.66
  Coverage of target region                               99.70%      99.60%      99.70%      99.70%
  Coverage of flanking region                             94.20%      93.70%      93.90%      95.50%
  Fraction of target covered with at least 20x            86.10%      85.10%      87.10%      89.10%
  Fraction of target covered with at least 10x            95.70%      94.90%      96.50%      96.80%
  Fraction of target covered with at least 4x             98.90%      98.60%      99.10%      99.00%
  Fraction of flanking region covered with at least 20x   18.70%      18.70%      18.50%      20.40%
  Fraction of flanking region covered with at least 10x   41.00%      40.80%      40.90%      44.30%
  Fraction of flanking region covered with at least 4x    71.00%      70.50%      70.50%      74.50%
  Mapping rate                                            99.49%      99.36%      99.37%      99.54%
  Duplicate rate                                          5.51%       5.58%       5.38%       5.97%

###### 

Whole exome sequencing data statistics

  **Items/samples**                 **23022**   **23031**   **23652**   **23878**
  --------------------------------- ----------- ----------- ----------- -----------
  Total variants                    84385       83618       85059       87055
  SNPs variants                     76627       76016       77235       78637
  INDEL variants                    7758        7602        7824        8418
  Novel SNPs variants               2751        2750        2708        2778
  Novel INDEL variants              1951        1875        1938        2155
  Novel functional SNPs variants    441         434         432         389
  Novel functional INDEL variants   63          56          59          58

###### 

CML candidate genes (known to be involved in CML)

  **Gene**   **Description**                                                           **Link**
  ---------- ------------------------------------------------------------------------- -----------------------------------------------
  JAK 2      Janus kinase 2                                                            <http://www.ncbi.nlm.nih.gov/pubmed/25657500>
  STAP2      signal transducing adaptor family member 2                                <http://www.ncbi.nlm.nih.gov/pubmed/22231445>
  IKZF1      IKAROS family zinc finger 1                                               <http://www.ncbi.nlm.nih.gov/pubmed/18408710>
  FANCD2     Fanconi anemia, complementation group D2                                  <http://www.ncbi.nlm.nih.gov/pubmed/21203397>
  COPS5      COP9 signalosome subunit 5                                                <http://www.ncbi.nlm.nih.gov/pubmed/21935931>
  SKP2       S-phase kinase-associated protein 2, E3 ubiquitin protein ligase          <http://www.ncbi.nlm.nih.gov/pubmed/20717963>
  SHC1       SHC (Src homology 2 domain containing) transforming protein 1             <http://www.ncbi.nlm.nih.gov/pubmed/10676660>
  GAB2       GRB2-associated binding protein 2                                         <http://www.ncbi.nlm.nih.gov/pubmed/12124177>
  GRB2       growth factor receptor-bound protein 2                                    <http://www.ncbi.nlm.nih.gov/pubmed/10887132>
  CRK        v-crk avian sarcoma virus CT10 oncogene homolog                           <http://www.ncbi.nlm.nih.gov/pubmed/8632906>
  DOK2       docking protein 2, 56kDa                                                  <http://www.ncbi.nlm.nih.gov/pubmed/15611294>
  DOK1       docking protein 1, 62kDa (downstream of tyrosine kinase 1)                <http://www.ncbi.nlm.nih.gov/pubmed/15611294>
  NEDD9      neural precursor cell expressed, developmentally down-regulated 9         <http://www.ncbi.nlm.nih.gov/pubmed/21848808>
  SGK223     homolog of rat pragma of Rnd2                                             <http://www.ncbi.nlm.nih.gov/pubmed/20697350>
  RhoA       ras homolog family member A                                               <http://www.ncbi.nlm.nih.gov/pubmed/22443473>
  LRRK1      leucine-rich repeat kinase 1                                              <http://www.ncbi.nlm.nih.gov/pubmed/20697350>
  CBL        Cbl proto-oncogene, E3 ubiquitin protein ligase                           <http://www.ncbi.nlm.nih.gov/pubmed/9195915>
  TWIST-1    twist family bHLH transcription factor 1                                  <http://www.ncbi.nlm.nih.gov/pubmed/21123820>
  PIK3R1     phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                   <http://www.ncbi.nlm.nih.gov/pubmed/23292937>
  INPPL1     inositol polyphosphate phosphatase-like 1                                 <http://www.ncbi.nlm.nih.gov/pubmed/10194451>
  HCK        HCK proto-oncogene, Src family tyrosine kinase                            <http://www.ncbi.nlm.nih.gov/pubmed/12592324>
  LYN        LYN proto-oncogene, Src family tyrosine kinase                            <http://www.ncbi.nlm.nih.gov/pubmed/12509383>
  HoxA9      homeobox A9                                                               <http://www.ncbi.nlm.nih.gov/pubmed/20141430>
  RKIP       phosphatidylethanolamine binding protein 1                                <http://www.ncbi.nlm.nih.gov/pubmed/25015191>
  CDC42      cell division cycle 42                                                    <http://www.ncbi.nlm.nih.gov/pubmed/19718053>
  NOX4       NADPH oxidase 4                                                           <http://www.ncbi.nlm.nih.gov/pubmed/25928540>
  PHLPP1     PH domain and leucine rich repeat protein phosphatase 1                   <http://www.ncbi.nlm.nih.gov/pubmed/19261608>
  PHLPP2     PH domain and leucine rich repeat protein phosphatase 2                   <http://www.ncbi.nlm.nih.gov/pubmed/19261608>
  STAT5      signal transducer and activator of transcription 5                        <http://www.ncbi.nlm.nih.gov/pubmed/25170113>
  PIK3R2     phosphoinositide-3-kinase, regulatory subunit 2 (beta)                    <http://www.ncbi.nlm.nih.gov/pubmed/18704194>
  PIK3CA     phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha   <http://www.ncbi.nlm.nih.gov/pubmed/18644865>
  MTOR       mechanistic target of rapamycin (serine/threonine kinase)                 <http://www.ncbi.nlm.nih.gov/pubmed/21715304>
  MYB        v-myb avian myeloblastosis viral oncogene homolog                         <http://www.ncbi.nlm.nih.gov/pubmed/2741649>
  USP18      ubiquitin specific peptidase 18                                           <http://www.ncbi.nlm.nih.gov/pubmed/17374743>
  BACH2      BTB and CNC homology 1, basic leucine zipper transcription factor 2       <http://www.ncbi.nlm.nih.gov/pubmed/11746976>
  SELE       selectin E                                                                <http://www.ncbi.nlm.nih.gov/pubmed/15674360>
  NOV        nephroblastoma overexpressed                                              <http://www.ncbi.nlm.nih.gov/pubmed/19623482>
  NUDCD1     NudC domain containing 1                                                  <http://www.ncbi.nlm.nih.gov/pubmed/11416219>
  FOLR3      folate receptor 3 (gamma)                                                 <http://www.ncbi.nlm.nih.gov/pubmed/8110752>
  MSI2       musashi RNA-binding protein 2                                             <http://www.ncbi.nlm.nih.gov/pubmed/12649177>
  RARA       retinoic acid receptor, alpha                                             <http://www.ncbi.nlm.nih.gov/pubmed/8180390>
  NUP98      nucleoporin 98kDa                                                         <http://www.ncbi.nlm.nih.gov/pubmed/24971156>
  VPREB1     pre-B lymphocyte 1                                                        <http://www.ncbi.nlm.nih.gov/pubmed/23881307>
  SOCS6      suppressor of cytokine signaling 6                                        <http://www.ncbi.nlm.nih.gov/pubmed/25172101>
  CSF3R      colony stimulating factor 3 receptor (granulocyte)                        <http://www.ncbi.nlm.nih.gov/pubmed/23656643>
  LHX2       LIM homeobox 2                                                            <http://www.ncbi.nlm.nih.gov/pubmed/14687986>
  NPM1       nucleophosmin (nucleolar phosphoprotein B23, numatrin)                    <http://www.ncbi.nlm.nih.gov/pubmed/25961029>
  ABCG2      ATP-binding cassette, sub-family G (WHITE), member 2                      <http://www.ncbi.nlm.nih.gov/pubmed/24123600>
  SMO        smoothened, frizzled class receptor                                       <http://www.ncbi.nlm.nih.gov/pubmed/18772113>
  NUMB       numb homolog (Drosophila)                                                 <http://www.ncbi.nlm.nih.gov/pubmed/21084860>
  miR-31     microRNA 31                                                               <http://www.ncbi.nlm.nih.gov/pubmed/22511990>
  TEC        tec protein tyrosine kinase                                               <http://www.ncbi.nlm.nih.gov/pubmed/22739199>
  miR-155    microRNA 155                                                              <http://www.ncbi.nlm.nih.gov/pubmed/22511990>
  RGS2       regulator of G-protein signaling 2                                        <http://www.ncbi.nlm.nih.gov/pubmed/7643615>
  BLK        BLK proto-oncogene, Src family tyrosine kinase                            <http://www.ncbi.nlm.nih.gov/pubmed/22797726>
  NAT8       N-acetyltransferase 8 (GCN5-related, putative)                            <http://www.ncbi.nlm.nih.gov/pubmed/24556617>
  miR-564    microRNA 564                                                              <http://www.ncbi.nlm.nih.gov/pubmed/22511990>
  ALOX5      arachidonate 5-lipoxygenase                                               <http://www.ncbi.nlm.nih.gov/pubmed/19503090>
  CD44       CD44 molecule                                                             <http://www.ncbi.nlm.nih.gov/pubmed/16998483>
  AXL        AXL receptor tyrosine kinase                                              <http://www.ncbi.nlm.nih.gov/pubmed/7521695>
  FOXO3      forkhead box O3                                                           <http://www.ncbi.nlm.nih.gov/pubmed/18644865>
  AKAP13     A kinase (PRKA) anchor protein 13                                         <http://www.ncbi.nlm.nih.gov/pubmed/8290273>
  AHI1       Abelson helper integration site 1                                         <http://www.ncbi.nlm.nih.gov/pubmed/22183070>
  SETBP1     SET binding protein 1                                                     <http://www.ncbi.nlm.nih.gov/pubmed/22566606>
  IRF8       interferon regulatory factor 8                                            <http://www.ncbi.nlm.nih.gov/pubmed/24242069>
  ETV6       ets variant 6                                                             <http://www.ncbi.nlm.nih.gov/pubmed/19480935>
  PDGFB      platelet-derived growth factor beta polypeptide                           <http://www.ncbi.nlm.nih.gov/pubmed/2660925>
  PDGFRA     platelet-derived growth factor receptor, alpha polypeptide                <http://www.ncbi.nlm.nih.gov/pubmed/19175693>
  GATA2      GATA binding protein 2                                                    <http://www.ncbi.nlm.nih.gov/pubmed/19304323>
  VEGFC      vascular endothelial growth factor C                                      <http://www.ncbi.nlm.nih.gov/pubmed/22169285>
  AKAP12     A kinase (PRKA) anchor protein 12                                         <http://www.ncbi.nlm.nih.gov/pubmed/15287943>
  SLC22A1    solute carrier family 22 (organic cation transporter), member 1           <http://www.ncbi.nlm.nih.gov/pubmed/23272163>
  PRKDC      protein kinase, DNA-activated, catalytic polypeptide                      <http://www.ncbi.nlm.nih.gov/pubmed/11264175>
  WNT        wingless-type MMTV integration site family                                <http://www.ncbi.nlm.nih.gov/pubmed/22823957>

Then we checked all filtered variants in each individual for these known genes to find cancer related genes but we did not identify any pathogenic mutation. Nevertheless, we identified polymorphisms in related genes, some of listed in [Table 4](#T4){ref-type="table"}.

###### 

Identified polymorphism in this study

  **Gene**   **NM_ID**      **Variant**   **Function**
  ---------- -------------- ------------- ----------------------
  AKAP12     NM_144497      rs3842128     Inframe insertion
                            rs10872670    Missense
                            rs3734799     Missense
  SETBP1     NM_001130110   rs3085861     Frameshift insertion
                            rs663651      Missense
                            rs3744825     Missense
  FOLR3      NM_000804      rs71891516    Frameshift insertion
  PIK3R2     NM_005027      rs1011320     Missense
  CD44       NM_001001389   rs9666607     Missense
                            rs1467558     Missense
  AXL        NM_001699      rs7249222     Missense
  AKAP13     NM_006738      rs2061821     Missense
                            rs2061822     Missense
                            rs2061824     Missense
  SLC22A1    NM_003057      rs683369      Missense
                            rs628031      Missense
  PDGFRA     NM_006206      rs35597368    Missense
  SON        NM_032195      rs13433428    Missense
                            rs13047599    Missense

Discussion
==========

In this study we performed exome sequencing as a high throughput technology to identify genetic alterations other than BCR-Abl translocation or those that lead to this cytogenetic translocation at molecular level which finally cause CML. We used public databases to prepare a list of cancer genes for further analysis; however, no pathogenic mutation was identified. Moreover, we analyzed functional variants (coding region and splice site variants) bioinformatically, but no pathogenic mutation was found. Logically, there are two main reasons for such results in our survey; disease nature and the technique characteristics.

A chromosomal translocation includes a DNA double strand break and repair more specifically, mis-repair.

Accordingly, all genes implicated in homologous recombination and non-homolegous end joining, as the two main DSB repair pathways, are putative candidate genes mutated before BCR-Abl translocation ([@B6]). Moreover, Alu elements have been involved in the pathogenesis of some complex translocations including BCR and ABL, but these are extremely rare ([@B7]).

Leukemogenic chromosomal translocations, including fusions between BCR and ABL are present in the peripheral blood of healthy individuals ([@B8]). It was controversial because for decades it had been proposed that these translocations unavoidably led to leukemia. There are important hints in these results. First, it forcefully implies that this oncogenic translocation is not adequate to produce malignancy, but it instead produces a "pre-malignant" clone that requires additional, complementary, events to transform fully the cell. On the other hand, this result shows that detection of an oncogenic translocation is not equivalent to detection of a malignancy ([@B9], [@B10]). Second, this result makes a possible explanation for the observation that mice manipulated to overexpress an oncogenic fusion protein often do not grow leukemia. In these mice, one oncogenic mutation is integrated in the mouse germline, but leukemic transformation is not triggered until additional mutation(s) occur spontaneously as the mouse ages. However, most of these putative mutations have not been characterized ([@B6]) and we did not identify any pathogenic mutation in related genes as well.

In this study; however some polymorphic variants were identified among them; SNPs rs683369 and rs628031 in SLC22A1, found in all subjects, have previously been studied in relation to imatinib response.

"SNP rs683369 and advanced disease stage are correlated with a high rate of loss of cytogenetic response or treatment failure to imatinib in CML patients" ([@B11]). We cannot determine the effect of this variant due to the chronic phase of the disease in our patients.

Moreover, Chowbay et al. revealed a sub-haplotypic region encompassing one exonic SNP (rs628031) surrounded by two intronic SNPs \[IVS6-878C.A (rs3798168) and IVS7+850C.T\] that is significantly associated with imatinib clearance ([@B12]). Except rs628031, two other polymorphisms of this sub-haplotypic region were not detected in our subjects.

Exome sequencing has been a fast and cost-effective tool to identify recurrent, specific mutations in solid tumors and leukemias ([@B13]--[@B15]). Nevertheless, this recent technique has some limitations too. Two main technical limitations in NGS, which impress exome-sequencing results, are homologous sequences and guanine cytosine (GC) bias ([@B16]) which lead to alignment errors. Another technical consideration with exome sequencing is that variants located in UTRs, intronic, promoter, and intergenic regulatory regions are mostly missed. Although it is often difficult to interpret novel variants in such regions, there are known pathogenic variants in many genes that lie outside the exons.

Conclusion
==========

It is the first report of exome sequencing in Philadelphia chromosome positive CML patients. We did not identify any pathogenic mutation in known cancer genes in our patients who can be due to CML pathogenesis or technical limitations.
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